What is COO's intrinsic value?

TickerWorth's blended fair value for The Cooper Companies, Inc. (COO) is $63.10 per share, versus a market price of $57.84 (priced within our range of $46.29 – $82.60).

Is COO overvalued or undervalued?

Priced within our range of $46.29 – $82.60 at $57.84. We don't call COO overvalued or undervalued from a range. This is an educational estimate, not advice.

What discount rate is used for COO?

A WACC of 8.6% and a terminal growth rate of 2.5%.

Is The Cooper Companies stock undervalued?

TickerWorth's fair value for The Cooper Companies, Inc. (COO) is $63.10 against a market price of $57.84. Our read: Priced within our range of $46.29 – $82.60. This is a model estimate, not investment advice.

The Cooper Companies (COO) DCF valuation and fair value

Our fair value for The Cooper Companies, Inc. (COO) is $63.10, built on a 8.6% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.

What growth is priced into The Cooper Companies stock?

no growth rate up to 300%/yr justifies the price under these economics This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $57.84. A model estimate, not investment advice.

The Cooper Companies (COO) insider trading

The most recent insider filing (SEC Form 4) for The Cooper Companies, Inc. (COO): Kurzius Lawrence Erik, Director, open-market buy on 2026-09-16. The latest filings are listed on this page. A disclosure, not a signal to trade.

COO · Intrinsic value

Is The Cooper Companies, Inc. (COO) overvalued or undervalued?

Name: The Cooper Companies, Inc. (COO) DCF intrinsic value
Creator: TickerWorth

TickerWorth's fair value for The Cooper Companies, Inc. (COO) is $63.10 a share, against the delayed market price of $57.84 (priced within our range of $46.29 – $82.60). no growth rate up to 300%/yr justifies the price under these economics We do not call it over- or undervalued from inside our range.

Model by Miraaj Patel · generated from a hand-researched model · Updated Oct 19, 2026 · How these pages are made

Open full COO analysis

Is COO fairly valued?

Fair value: $63.10
Market price: $57.84
Upside to fair value: +9.1%
Verdict: Priced within our range of $46.29 – $82.60

Price as of 19 Oct 2026, 17:01 UTC · Prices are delayed.

Fair value against the delayed market price: Priced within our range of $46.29 – $82.60.

Reverse DCF: no growth rate up to 300%/yr justifies the price under these economics

What is COO's TickerWorth Score?

C54/100

Middle of the pack — real strengths and real weaknesses

Compared with Healthcare companies in US

Its strongest point: looks cheap on the numbers. Its weakest: recent price trend has been weak.

Value · 74 of 100
Cheaper than 74% of Healthcare companies in US
Price vs worth · 57 of 100
Quality · 62 of 100
More profitable than 62% of Healthcare companies in US
Financial health · 30 of 100
Financially stronger than 30% of Healthcare companies in US
Growth · 57 of 100
Growing faster than 57% of Healthcare companies in US
Momentum · 12 of 100
Outperformed 12% of Healthcare companies in US over the past year

Confidence: High confidence · Scored 19 Oct 2026, 17:01 UTC

Get the Undervalued Company of the Week.

Where the numbers come from

Hand-researched model

What the modeller flagged

AMORTIZATION IS NOT CHARGED AS A COST. The margin is struck before ~$190M/yr of acquired-intangible amortization, i.e. this model assumes Cooper has stopped buying companies — true lately (acquisition spend $10.5M in FY2025, $5.4M in 9M FY2026; buybacks are the stated priority) but not of its history (Sauflon, Paragard ~$1.1B, Generate ~$1.6B, Cook Medical $300M). Under the house IBM/GEHC treatment — amortization kept in EBIT as the standing charge for an acquisition habit — the value would be ~$44.58 — about $11/share lower. If Cooper resumes buying, that is the better number.
TERMINAL VALUE IS ~76% OF ENTERPRISE VALUE — just above the 75% line. Across reasonable WACC and terminal-growth combinations the value spans a wide range; treat the cent with suspicion.
YEAR-1 FCF IS ~62% ABOVE THE FY2025 REPORTED FCF ($703M modeled vs $433.7M) — past the 20% line, and explained: the model is unlevered (FY2025 cash interest was $115.1M), FY2025 capex was 8.9% of revenue vs ~7.9% in FY2026, and FY2025 carried the Q4 reorganization. FY2026 itself already shows $528.1M of FCF in nine months (vs $283.8M a year earlier), so the model's Year 1 is BELOW the company's run-rate before the litigation payment, and the model's FY2026-28 cash flow sits below management's >$2.2B target.
COST OF DEBT IS MARGINAL (6.5%), NOT THE ~3.4% Q3 REALISED RATE on swapped bank debt; no public rating verified.
Beta used as published (0.825); not normalized.
SBC ($70.5M in FY2025, 1.7% of revenue) is expensed inside the margin; dilution is captured by the diluted share count.

COO DCF valuation, input by input

TickerWorth's fair value for The Cooper Companies, Inc. (COO) is $63.10 a share, against the delayed market price of $57.84 (priced within our range of $46.29 – $82.60). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.

Read the full reasoning

One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values COO at about $55.41 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.

The valuation discounts The Cooper Companies, Inc.'s projected free cash flows at a weighted-average cost of capital (WACC) of 8.6%, with a long-run terminal growth rate of 2.5%. About 76% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.

Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, COO's modeled DCF value ranges from about $36.70 to $99.63 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.

How to read this page: the DCF fair value is what The Cooper Companies, Inc. would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of COO's intrinsic value. Figures update as new filings and prices come in.

Every input behind COO's DCF

Input	Value	Source
Base-year revenueCooperCompanies FY2025 10-K (accession 0001628280-25-055615, filed 2025-12-05): Net sales FY2025 $4,092.4M (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, year ended 31 Oct 2025): +5% reported, +4% organic. CooperVision $2,743.8M (67%), CooperSurgical $1,348.6M (33%) per the Q4 release. FISCAL YEAR ENDS 31 OCTOBER, so FY2026 (Year 1) ends 31 Oct 2026 and three of its four quarters are already reported. CROSS-CHECK: 9M FY2026 revenue $3,171.8M, +4.8% on 9M FY2025's $3,027.3M (Q3 alone +0.6%).	$4,092,400,000	CooperCompanies FY2025 10-K (accession 0001628280-25-055615, filed 2025-12-05): Net sales FY2025 $4,092.4M (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, year ended 31 Oct 2025): +5% reported, +4% organic. CooperVision $2,743.8M (67%), CooperSurgical $1,348.6M (33%) per the Q4 release. FISCAL YEAR ENDS 31 OCTOBER, so FY2026 (Year 1) ends 31 Oct 2026 and three of its four quarters are already reported. CROSS-CHECK: 9M FY2026 revenue $3,171.8M, +4.8% on 9M FY2025's $3,027.3M (Q3 alone +0.6%).
Base EBIT marginCooperCompanies FY2025 10-K (accession 0001628280-25-055615, filed 2025-12-05): GAAP operating income $682.9M / $4,092.4M = 16.69%, AS REPORTED. NOT the basis of the forecast — see forecast.ebit_margin. The forecast margin is struck BEFORE amortization of acquired intangibles ($199.2M in FY2025) and AFTER a standing 1.5%-of-revenue charge for Cooper's recurring 'non-recurring' items. On that basis FY2025 was 24.3%: non-GAAP operating income $1,055.8M (25.8%, per the Q4 release reconciliation) less 1.5%. FY2025 GAAP was unusually depressed by $173.7M of non-amortization charges (4.2% of revenue: $50.9M business optimization from the Q4 reorganization, $51.8M product-line exit at CooperSurgical, $43.2M integration, $21.9M EU MDR, $5.9M other) against $64.4M (1.65%) in FY2024. Kept as reported here so the base line matches the filing; this base value is not used by the DCF arithmetic except in the site's peak-margin check, which it does not affect (Y1 is higher).	16.7%	CooperCompanies FY2025 10-K (accession 0001628280-25-055615, filed 2025-12-05): GAAP operating income $682.9M / $4,092.4M = 16.69%, AS REPORTED. NOT the basis of the forecast — see forecast.ebit_margin. The forecast margin is struck BEFORE amortization of acquired intangibles ($199.2M in FY2025) and AFTER a standing 1.5%-of-revenue charge for Cooper's recurring 'non-recurring' items. On that basis FY2025 was 24.3%: non-GAAP operating income $1,055.8M (25.8%, per the Q4 release reconciliation) less 1.5%. FY2025 GAAP was unusually depressed by $173.7M of non-amortization charges (4.2% of revenue: $50.9M business optimization from the Q4 reorganization, $51.8M product-line exit at CooperSurgical, $43.2M integration, $21.9M EU MDR, $5.9M other) against $64.4M (1.65%) in FY2024. Kept as reported here so the base line matches the filing; this base value is not used by the DCF arithmetic except in the site's peak-margin check, which it does not affect (Y1 is higher).
Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast	4% → 4% → 4% → 4% → 4%	ESTIMATEAssumption — TickerWorth's 5-year explicit forecast
Risk-free rateUS 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation; program-wide rate shared by every researched model in this run.	5.2%	US 10Y Treasury constant maturity (FRED DGS10): 5.24% on 2026-10-01, the latest published observation; program-wide rate shared by every researched model in this run.
BetaYahoo Finance / yfinance published beta (5Y monthly): Published 5Y-monthly beta 0.825, used as published — not normalized. Cooper is a medical-device company with moderate leverage (net debt ~2.0x EBITDA), so there is no strong reason to move it; the activist and strategic-review swings of 2025-26 are a handful of monthly points. Raising it to 1.0 would cut the value to ~$48; each 0.1 of beta is worth ~$4/share.	0.82	Yahoo Finance / yfinance published beta (5Y monthly): Published 5Y-monthly beta 0.825, used as published — not normalized. Cooper is a medical-device company with moderate leverage (net debt ~2.0x EBITDA), so there is no strong reason to move it; the activist and strategic-review swings of 2025-26 are a handful of monthly points. Raising it to 1.0 would cut the value to ~$48; each 0.1 of beta is worth ~$4/share.
Terminal growthESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP), kept for comparability. Contact lenses are a slow-growing, recurring-purchase market (Cooper's own organic growth ran ~4-5% for years) and fertility has structural tailwinds, so 2.5% is not generous for this business. 2.0% takes ~$4/share off. Well below the 8.64% WACC.	2.5%	ESTIMATEAssumption — house default: House default 2.5% (roughly long-run nominal GDP), kept for comparability. Contact lenses are a slow-growing, recurring-purchase market (Cooper's own organic growth ran ~4-5% for years) and fertility has structural tailwinds, so 2.5% is not generous for this business. 2.0% takes ~$4/share off. Well below the 8.64% WACC.
Diluted sharesCooperCompanies Q3 FY2026 10-Q (accession 0001628280-26-061160, filed 2026-09-09): Q3 FY2026 weighted-average diluted shares 193.4M (200.0M a year earlier). Period-end outstanding was already lower, 190.1M at 31 Jul 2026, after 4.9M shares were repurchased in Q3 for $339.1M (avg $69.16); using the weighted count is ~$0.90/share conservative. Buyback authorization raised from $2B to $3B on 2026-09-09, ~$1.5B remaining. No convertibles.	193M	CooperCompanies Q3 FY2026 10-Q (accession 0001628280-26-061160, filed 2026-09-09): Q3 FY2026 weighted-average diluted shares 193.4M (200.0M a year earlier). Period-end outstanding was already lower, 190.1M at 31 Jul 2026, after 4.9M shares were repurchased in Q3 for $339.1M (avg $69.16); using the weighted count is ~$0.90/share conservative. Buyback authorization raised from $2B to $3B on 2026-09-09, ~$1.5B remaining. No convertibles.
Market priceDelayed quote · as of 2026-10-19 17:01 UTC	$57.84	Delayed quote · as of 2026-10-19 17:01 UTC

Change COO's assumptions

The discount-rate dial and the editable model

Pro

Change growth, margin and WACC yourself — Pro (7-day free trial, card required).

Start free trial Try it on Apple

What does The Cooper Companies, Inc. do?

What does it do?

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. It operates in the Medical Instruments & Supplies industry (Healthcare sector), headquartered in United States. The company employs roughly 15,000 people.

How does it make money?

The business turns $4.2B in annual revenue into profit. Out of every $100 of sales, about $21 is left as operating profit (operating margin of 20.8%), after a 66% gross margin on the products/services it sells. After all costs, taxes and interest, 13.5% of revenue becomes bottom-line net profit.

Is it financially healthy?

Financially it looks mixed: carries modest debt (0.3× equity), can just cover its short-term bills (1.2× current ratio), and is currently profitable.

Who at COO filed insider trades?

Recent insider filings for The Cooper Companies, Inc.
Date	Insider	Relationship	What happened	Value	Filing
16 Sept 2026	Kurzius Lawrence Erik	Director	Open-market buy	$549,320.00	Form 4 for Kurzius Lawrence Erik (opens sec.gov in a new tab)
14 Sept 2026	Rosebrough Walter M Jr	Director	Open-market buy	$162,870.00	Form 4 for Rosebrough Walter M Jr (opens sec.gov in a new tab)
14 Sept 2026	Kurzius Lawrence Erik	Director	Open-market buy	$539,150.00	Form 4 for Kurzius Lawrence Erik (opens sec.gov in a new tab)
11 Sept 2026	Rosebrough Walter M Jr	Director	Open-market buy	$378,770.00	Form 4 for Rosebrough Walter M Jr (opens sec.gov in a new tab)
1 Apr 2026	Rosebrough Walter M Jr	Director	Option exercise	—	Form 4 for Rosebrough Walter M Jr (opens sec.gov in a new tab)
1 Apr 2026	WEISS ROBERT S	Director	Option exercise	—	Form 4 for WEISS ROBERT S (opens sec.gov in a new tab)

A disclosure, not a signal to trade. Source: SEC EDGAR (Form 4). Older filings and the 90-day buying-and-selling read are part of Pro. See plans

Common questions

What is COO's intrinsic value?
TickerWorth's blended fair value for The Cooper Companies, Inc. (COO) is $63.10 per share, versus a market price of $57.84 (priced within our range of $46.29 – $82.60).
Is COO overvalued or undervalued?
Priced within our range of $46.29 – $82.60 at $57.84. We don't call COO overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for COO?
A WACC of 8.6% and a terminal growth rate of 2.5%.
Is The Cooper Companies stock undervalued?
TickerWorth's fair value for The Cooper Companies, Inc. (COO) is $63.10 against a market price of $57.84. Our read: Priced within our range of $46.29 – $82.60. This is a model estimate, not investment advice.
The Cooper Companies (COO) DCF valuation and fair value
Our fair value for The Cooper Companies, Inc. (COO) is $63.10, built on a 8.6% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into The Cooper Companies stock?
no growth rate up to 300%/yr justifies the price under these economics This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $57.84. A model estimate, not investment advice.
The Cooper Companies (COO) insider trading
The most recent insider filing (SEC Form 4) for The Cooper Companies, Inc. (COO): Kurzius Lawrence Erik, Director, open-market buy on 2026-09-16. The latest filings are listed on this page. A disclosure, not a signal to trade.